In last trading session, Zymeworks BC Inc (NASDAQ:ZYME) saw 0.37 million shares changing hands with its beta currently measuring 1.23. Company’s recent per share price level of $12.57 trading at $0.05 or 0.40% at ring of the bell on the day assigns it a market valuation of $881.75M. That closing price of ZYME’s stock is at a discount of -40.81% from its 52-week high price of $17.70 and is indicating a premium of 36.6% from its 52-week low price of $7.97. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.64 million shares which gives us an average trading volume of 641.82K if we extend that period to 3-months.

For Zymeworks BC Inc (ZYME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.73 in the current quarter.

Zymeworks BC Inc (NASDAQ:ZYME) trade information

Upright in the green during last session for gaining 0.40%, in the last five days ZYME remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $12.57 price level, adding 2.78% to its value on the day. Zymeworks BC Inc’s shares saw a change of -14.14% in year-to-date performance and have moved 9.02% in past 5-day. Zymeworks BC Inc (NASDAQ:ZYME) showed a performance of 1.78% in past 30-days. Number of shares sold short was 5.41 million shares which calculate 7.2 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 26 to the stock, which implies a rise of 51.65% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would jump 4.53% in reaching the projected high whereas dropping to the targeted low would mean a gain of 4.53% for stock’s current value.

Zymeworks BC Inc (ZYME) estimates and forecasts

This year revenue growth is estimated to rise 23.73% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 20.65M for the same. And 6 analysts are in estimates of company making revenue of 18.02M in the next quarter. Company posted 10.03M and 19.24M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.81% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -3.28% while estimates for its earnings growth in next 5 years are of -1.14%.

Zymeworks BC Inc (NASDAQ:ZYME)’s Major holders

Insiders are in possession of 0.19% of company’s total shares while institution are holding 102.11 percent of that, with stock having share float percentage of 102.29%. Investors also watch the number of corporate investors in a company very closely, which is 102.11% institutions for Zymeworks BC Inc that are currently holding shares of the company. ECOR1 CAPITAL, LLC is the top institutional holder at ZYME for having 13.44 million shares of worth $114.35 million. And as of 2024-06-30, it was holding 17.59 of the company’s outstanding shares.

The second largest institutional holder is BVF INC/IL, which was holding about 5.87 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.684 of outstanding shares, having a total worth of $49.95 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.89 shares of worth $23.75 million or 3.00% of the total outstanding shares. The later fund manager was in possession of 1.44 shares on Mar 31, 2025 , making its stake of worth around $18.08 million in the company or a holder of 2.28% of company’s stock.